


Labcorp offers the leading HCV menu for complete care decisions



Laboratory tests to aid in the screening, evaluation and management of HCV include:



*Sustained virologic response: undetectable HCV RNA, using a sensitive assay, at least 12 weeks after treatment completion.³

Labcorp offers the leading HCV menu for complete care decisions

Labcorp offers a comprehensive menu of HCV tests to aid in screening, diagnosis and monitoring of patients with hepatitis C virus (HCV).

Our portfolio of HCV tests includes the following tests that are represented in the diagram on the previous page. For complete test options, visit our online Test Menu at labcorp.com/test-menu/search.

Hepatitis C virus (HCV) antibody with reflex to quantitative real-time PCR (144050)

The CDC introduced new recommendations for HCV screening in April 2020. Universal HCV screening should be performed at least once per lifetime for all adults older than 18 years and for all pregnant women during each pregnancy, except in settings where the prevalence of HCV infection is less than 0.1%.

One-time HCV screening should be performed regardless of age or setting prevalence among those with specified conditions or exposures, including HIV, history of injection drug use, history of certain medical conditions requiring hemodialysis or those with persistently abnormal ALT levels, history of transfusions or history of organ transplant prior to 1992, history of occupational needle sticks or other exposures to HCV-positive blood and children born to mothers with HCV infection.

Routine, periodic testing for people with ongoing risk factors such as injection drug use or any person who requests HCV testing.¹

- Labcorp offers test 144050, which uses FDA-approved antibody and NAT tests to aid in the screening and follow up of those who are indicated for HCV evaluation. HCV antibody testing and HCV RNA testing may also be ordered individually
- Results from the quantitative RNA test can be used to confirm an active HCV infection and provide an accurate measurement of a patient's viral load⁵

HCV, quantitative, real-time PCR-nongraphical (550080)

HCV, quantitative, real-time PCR-graphical (550070)

- Quantifies patient's viral load. The quantifiable range of the assay is 15 IU/ml to 100,000,000 IU/ml
- Can provide a baseline assessment prior to therapy in treatment-naïve patients. Also used to monitor patients on therapy and posttherapy³

Hepatitis C virus (HCV), quantitative, RNA PCR (nongraphical) with reflex to genotyping (550090)

Hepatitis C virus (HCV), quantitative, RNA PCR (graphical) with reflex to genotyping (550100)

- Quantifies patient's viral load and allows genotyping of the six major HCV types

Hepatitis C virus (HCV) antibody cascade to quantitative PCR and genotyping (144127)

- Antibody cascade with reflex tests for diagnosis and management of HCV

HCV genotyping (550475)

- Provides genotyping of the six major HCV types and their most common subtypes

HCV FibroSure® (550123)

- Assessment of liver status following diagnosis of HCV
- Noninvasive blood test for six biochemical markers that provides METAVIR fibrosis staging and necroinflammatory grading
- HCV FibroSure has been validated against liver biopsy and has demonstrated diagnostic value comparable to liver biopsy in assessing fibrosis⁶

HCV GenoSure® NS3/4A (550540)

- Assessment of NS3/4A inhibitor susceptibility by nucleic acid sequencing for patients with documented HCV genotype 1a or 1b

Hepatitis C virus (HCV) NS5A drug resistance assay (550325)

- Assessment of NS5A inhibitor susceptibility by nucleic acid sequencing for patients with documented HCV genotype 1a or 1b
- Recommended for patients with genotype 1a, treatment naïve or experienced, being considered for elbasvir/grazoprevir
- Consider for treatment experienced patients with genotype 1a considered for ledipasvir/sofosbuvir³

Hepatitis C virus (HCV) genotype 3 NS5A drug resistance assay (550603)

- Assessment of NS5A inhibitor susceptibility by nucleic acid sequencing for patients with documented HCV genotype 3
- Recommended for treatment-experienced patients without cirrhosis and treatment-naïve patients with cirrhosis, being considered for sofosbuvir/velpatasvir²

Hepatitis C virus (HCV) NS5B drug resistance assay (550505)

- Assessment of NS5B polymerase inhibitor susceptibility by nucleic acid sequencing for patients with documented HCV genotype 1a or 1b

HBV baseline evaluation, HCV direct-acting antivirals (144547)

- Hepatitis B surface antigen (HBsAg) screen [006510]; Hepatitis B surface antibody (anti-HBs) [006395]; Hepatitis B core antibody, total (anti-HBc) [006718]
- Reflex of HBsAg + to: HBV quant DNA [551610]

HBV baseline evaluation

- HIV p24 antigen/antibody with reflex to confirmation [083935]

References

1. Schillie S, Webster C, Osborne M, et al. CDC recommendations for Hepatitis C screening among adults—United States, 2020. *MMWR*, April 10, 2020, 69(2):1-17.
2. European Association for the Study of the Liver. Practice Guidelines: EASL recommendations on treatment of hepatitis C: Final update on the series. *J of Hepatology*, 2020, 73:1170-1218.
3. American Association for the Study of Liver Diseases (AASLD); Infectious Diseases of America (IDSA). Simplified HCV treatment for treatment-naïve adults without cirrhosis. HCV Guidance Recommendations for Testing, Managing and Treating Hepatitis C. Updated October 24, 2022. Accessed May 10, 2023. hcvguidelines.org.
4. Zepatier™ (elbasvir and grazoprevir) tablets, for oral use [package insert]. Initial US Approval: 2016. Whitehouse Station, NJ: Merck and Co Inc; 2016-2022.
5. Roche Molecular Systems. COBAS®AmpliPrep/COBAS®TaqMan® HCV Test, version 2.0, Indianapolis, Ind. Roche Diagnostics, 2016.
6. Poynard T, Morra R, Halfon P, et al. Meta-analysis of FibroTest diagnostic value in chronic liver disease. *BMC Gastro*. 2007 Oct 15;7:40.